F. Hurbin

发表

Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics

N. Djebli, D. Fabre, X. Boulenc, 2015, Drug Metabolism and Disposition.

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies

L. Bergougnan, O. Nicolas, D. Angiolillo, 2011, Clinical pharmacology and therapeutics.

Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II

X. Nicolas, N. Djebli, D. Fabre, 2018, Clinical Pharmacokinetics.

Comparison of the stability of some major cytochrome P450 and conjugation reactions in rat, dog and human hepatocyte monolayers

D. Jaeck, F. Hurbin, P. Coassolo, 2010, European Journal of Drug Metabolism and Pharmacokinetics.

Estimation of flavin-containing monooxygenase activity in intact hepatocyte monolayers of rat, hamster, rabbit, dog and human by using N-oxidation of benzydamine.

D. Jaeck, F. Hurbin, P. Coassolo, 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Clopidogrel Pharmacodynamics and Pharmacokinetics in the Fed and Fasted State: A Randomized Crossover Study of Healthy Men

F. LaCreta, X. Boulenc, E. Sultan, 2012, Journal of clinical pharmacology.

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

D. Fabre, F. Hurbin, Jean-Marie Martinez, 2018, Clinical Pharmacokinetics.

First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection

P. Deutsch, L. Bergougnan, Anthony J. Muslin, 2020, British journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Alirocumab, and Effects on PCSK9 and Low-Density Lipoprotein Cholesterol, in Japanese and Non-Japanese Patients

S. Horiuchi, Y. Shitara, F. Hurbin, 2019, Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics.

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

P. Deutsch, L. Bergougnan, Anthony J. Muslin, 2020, medRxiv.

An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma

N. Brémond, P. Savi, Sébastien Roy, 2011, Thrombosis and Haemostasis.

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

Deepak L. Bhatt, E. Vicaut, L. Bergougnan, 2011, Clinical pharmacology and therapeutics.

Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies

S. Khier, N. Djebli, D. Fabre, 2017, Clinical Pharmacokinetics.

Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite

N. Djebli, X. Boulenc, F. Hurbin, 2012, Drug Metabolism and Disposition.

DMD062596 510..522

N. Djebli, D. Fabre, X. Boulenc, 2015 .

Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa

N. Brémond, P. Savi, Sébastien Roy, 2012 .

Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease

P. Miossec, D. Fabre, F. Hurbin, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials

D. Fabre, F. Hurbin, G. Tuffal, 2023, Therapeutic drug monitoring.